About this trial
The objective of this study is to prove that treatment with primary cytoreductive surgery in combination with HIPEC (treatment arm) improves outcome compared to primary cytoreductive surgery without HIPEC (standard arm) with acceptable morbidity, in patients with FIGO stage III epithelial ovarian cancer who are eligible for primary cytoreductive surgery with no residual disease, or residual disease up to 2.5 mm.
Patient Profile
This trial is open to females aged 18 years or older who have a formal diagnosis from their doctor of epithelial ovarian, fallopian tube, or extra-ovarian cancer.
Epithelial ovarian cancer is a type of cancer that originates in the cells covering the surface of the ovaries.
In Stage III, the cancer typically extends beyond the ovaries and may involve the pelvic organs, such as the fallopian tubes or the lining of the abdominal cavity. It may also involve nearby lymph nodes.
Where’s this trial being run?
Mater Misericordiae University Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | OVHIPEC-2 |
|---|---|
| Number: | 20-07 |
| Full Title: | Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial |
| Principal Investigator: | Prof Donal Brennan |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | The Netherlands Cancer Institute/DGOG |
| Recruitment Started: |
Global: January 2020 Ireland: August 2022 |
| Global Recruitment Target: | 538 |
|---|---|
| Ireland Recruitment Target: | 20 |